- Home
- BCG vs BLRX Comparison
BCG vs BLRX Comparison
Compare BCG & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- BLRX
- Stock Information
- Founded
- BCG 2016
- BLRX 2003
- Country
- BCG United States
- BLRX Israel
- Employees
- BCG N/A
- BLRX N/A
- Industry
- BCG
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- BLRX Health Care
- Exchange
- BCG Nasdaq
- BLRX Nasdaq
- Market Cap
- BCG 32.5M
- BLRX 17.2M
- IPO Year
- BCG N/A
- BLRX 2011
- Fundamental
- Price
- BCG $1.73
- BLRX $3.88
- Analyst Decision
- BCG
- BLRX Strong Buy
- Analyst Count
- BCG 0
- BLRX 2
- Target Price
- BCG N/A
- BLRX $19.00
- AVG Volume (30 Days)
- BCG 24.3K
- BLRX 32.7K
- Earning Date
- BCG 11-13-2025
- BLRX 08-14-2025
- Dividend Yield
- BCG N/A
- BLRX N/A
- EPS Growth
- BCG N/A
- BLRX N/A
- EPS
- BCG N/A
- BLRX N/A
- Revenue
- BCG $173,961,000.00
- BLRX $17,251,000.00
- Revenue This Year
- BCG N/A
- BLRX N/A
- Revenue Next Year
- BCG N/A
- BLRX N/A
- P/E Ratio
- BCG N/A
- BLRX N/A
- Revenue Growth
- BCG 7.45
- BLRX 1.19
- 52 Week Low
- BCG $1.45
- BLRX $2.30
- 52 Week High
- BCG $6.55
- BLRX $26.80
- Technical
- Relative Strength Index (RSI)
- BCG 42.23
- BLRX 51.00
- Support Level
- BCG $1.75
- BLRX $3.68
- Resistance Level
- BCG $2.10
- BLRX $4.11
- Average True Range (ATR)
- BCG 0.15
- BLRX 0.25
- MACD
- BCG -0.01
- BLRX 0.03
- Stochastic Oscillator
- BCG 38.48
- BLRX 48.94
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.